premier report revenu estim higher
model share repurchas quarter lift ep estim
vs net admin fee rose y/i continu custom contract
penetr product revenu declin mostli account
chang offset oncolog growth quarter divestitur specialti rx
busi allevi recent pressur drag
growth margin premier anticip divestitur specialti rx
decreas revenu increas adj ebitda margin
due lower margin divest entiti reiter outperform
report revenu vs estimate consensu adj ebitda
vs estimate consensu adj ep vs
revenu guidanc seen near
midpoint vs estim consensu re-affirmed adj
ebitda guidanc seen lower end vs estim
consensu compani re-affirmed adj ep guid
seen near midpoint vs estim consensu segment
exit specialti pharma exit specialti pharma acro
commcar close sell asset procar
plu max inventori expect adj ebitda margin rise
revenue impact ad pre-tax incom
immateri ebitda ep cf impact non-cash impair
estim without specialti rx expect divestitur specialti
rx adjust revenu lower
exclud specialti rx direct sourc busi product segment expect
mid-high single-digit growth model
product revenu lower share count increas adj ep
chang estim revenu decreas
mainli due lower suppli chain revenu adj ep
increas higher share repurchas decreas share count
anticip specialti rx divestitur impact
number henc chang estim unrel divestitur
year price histori
organ gpo perform
us
analyst certif import disclosur see disclosur
